Search
Idarucizumab
go.drugbank.com/drugs/DB09264ApprovedAs a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease … Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalThis latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. … [L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Cinnamaldehyde
go.drugbank.com/drugs/DB14184ApprovedIt occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test. … Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour.
Synonyms: (E)-3-Phenylpropenal, (E)-3-Phenyl-propenalDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnThe FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications. … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigationaleffects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnTemafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. … It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab].
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalbinding at the ATP domain of the epidermal growth factor receptor family kinase domains. … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed.
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors